195 related articles for article (PubMed ID: 37971411)
1. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
[TBL] [Abstract][Full Text] [Related]
2. Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Ascierto PA; Casula M; Bulgarelli J; Pisano M; Piccinini C; Piccin L; Cossu A; Mandalà M; Ferrucci PF; Guidoboni M; Rutkowski P; Ferraresi V; Arance A; Guida M; Maiello E; Gogas H; Richtig E; Fierro MT; Lebbe C; Helgadottir H; Queirolo P; Spagnolo F; Tucci M; Del Vecchio M; Cao MG; Minisini AM; De Placido S; Sanmamed MF; Mallardo D; Paone M; Vitale MG; Melero I; Grimaldi AM; Giannarelli D; Dummer R; Sileni VC; Palmieri G
Nat Commun; 2024 Jan; 15(1):146. PubMed ID: 38167503
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of immune checkpoint inhibitors and BRAF/MEK inhibitors among veteran patients with cutaneous melanoma.
Kim DY; Swetter SM; Huhmann L; Dizon MP; Ferguson JM; Osborne TF; Spence AC; Ziad A; Fillmore N; Hartman RI
J Am Acad Dermatol; 2024 Mar; 90(3):620-623. PubMed ID: 37924953
[No Abstract] [Full Text] [Related]
4. Efficiency and tolerance of second-line triple BRAF inhibitor/MEK inhibitor/anti-PD1 combined therapy in BRAF mutated melanoma patients with central nervous system metastases occurring during first-line combined targeted therapy: a real-life survey.
Fabre M; Lamoureux A; Meunier L; Samaran Q; Lesage C; Girard C; Du Thanh A; Moulis L; Dereure O
Melanoma Res; 2024 Jun; 34(3):241-247. PubMed ID: 38546723
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma.
Woo TE; Stukalin I; Ding PQ; Goutam S; Sander M; Ewanchuk B; Cheung WY; Heng DYC; Cheng T
Curr Oncol; 2023 Sep; 30(10):8936-8947. PubMed ID: 37887546
[No Abstract] [Full Text] [Related]
6. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ; Dimitriou F; Grover P; Hassel JC; Erdmann M; Forschner A; Johnson DB; Váraljai R; Lodde G; Placke JM; Krefting F; Zaremba A; Ugurel S; Roesch A; Schulz C; Berking C; Pöttgen C; Menzies AM; Long GV; Dummer R; Livingstone E; Schadendorf D; Zimmer L
Eur J Cancer; 2024 May; 202():113976. PubMed ID: 38484692
[TBL] [Abstract][Full Text] [Related]
8. Combined immunotherapy in melanoma patients with brain metastases: A multicenter international study.
Mandalà M; Lorigan P; Sergi MC; Benannoune N; Serra P; Vitale MG; Giannarelli D; Arance AM; Couselo EM; Neyns B; Tucci M; Guida M; Spagnolo F; Rossi E; Occelli M; Queirolo P; Quaglino P; Depenni R; Merelli B; Placzke J; Di Giacomo AM; Del Vecchio M; Indini A; da Silva IP; Menzies AM; Long GV; Robert C; Rutkowski P; Ascierto PA
Eur J Cancer; 2024 Mar; 199():113542. PubMed ID: 38266540
[TBL] [Abstract][Full Text] [Related]
9. A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAF
Dayimu A; Gupta A; Matin RN; Nobes J; Board R; Payne M; Rao A; Fusi A; Danson S; Eccles B; Carser J; Brown CO; Steven N; Bhattacharyya M; Brown E; Gonzalez M; Highley M; Pickering L; Kumar S; Waterston A; Burghel G; Demain L; Baker E; Wulff J; Qian W; Twelves S; Middleton M; Corrie P
Eur J Cancer; 2024 Jan; 196():113455. PubMed ID: 38029480
[TBL] [Abstract][Full Text] [Related]
10. The combination of stereotactic radiosurgery with immune checkpoint inhibition or targeted therapy in melanoma patients with brain metastases: a retrospective study.
Martins F; Schiappacasse L; Levivier M; Tuleasca C; Cuendet MA; Aedo-Lopez V; Gautron Moura B; Homicsko K; Bettini A; Berthod G; Gérard CL; Wicky A; Bourhis J; Michielin O
J Neurooncol; 2020 Jan; 146(1):181-193. PubMed ID: 31836957
[TBL] [Abstract][Full Text] [Related]
11. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
12. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Meier F; Garzarolli M; Weichenthal M; Kähler K; Grimmelmann I; Gutzmer R; Utikal J; Terheyden P; Herbst R; Haferkamp S; Pfoehler C; Forschner A; Leiter U; Ziller F; Meiss F; Ulrich J; Kreuter A; Gebhardt C; Welzel J; Schilling B; Kaatz M; Scharfetter-Kochanek K; Dippel E; Nashan D; Sachse M; Weishaupt C; Löffler H; Gambichler T; Loquai C; Heinzerling L; Grabbe S; Debus D; Schley G; Hassel JC; Weyandt G; Trommer M; Lodde G; Placke JM; Zimmer L; Livingstone E; Becker JC; Horn S; Schadendorf D; Ugurel S
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028819
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
Pires da Silva I; Zakria D; Ahmed T; Trojanello C; Dimitriou F; Allayous C; Gerard C; Zimmer L; Lo S; Michielin O; Lebbe C; Mangana J; Ascierto PA; Johnson DB; Carlino M; Menzies A; Long G
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798536
[TBL] [Abstract][Full Text] [Related]
14. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
15. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
McQuade JL; Daniel CR; Hess KR; Mak C; Wang DY; Rai RR; Park JJ; Haydu LE; Spencer C; Wongchenko M; Lane S; Lee DY; Kaper M; McKean M; Beckermann KE; Rubinstein SM; Rooney I; Musib L; Budha N; Hsu J; Nowicki TS; Avila A; Haas T; Puligandla M; Lee S; Fang S; Wargo JA; Gershenwald JE; Lee JE; Hwu P; Chapman PB; Sosman JA; Schadendorf D; Grob JJ; Flaherty KT; Walker D; Yan Y; McKenna E; Legos JJ; Carlino MS; Ribas A; Kirkwood JM; Long GV; Johnson DB; Menzies AM; Davies MA
Lancet Oncol; 2018 Mar; 19(3):310-322. PubMed ID: 29449192
[TBL] [Abstract][Full Text] [Related]
16. The combination of ipilimumab and nivolumab is still not reimbursed for BRAF-mutated melanoma patients in France: An unacceptable medical situation that raises ethical concerns.
Amini-Adle M; Arnault JP; Aubin F; Beneton N; Bens G; Brunet-Possenti F; Célerier P; Charles J; Crumbach L; Dalac S; Darras S; De Quatrebarbes J; Dinulescu M; Dutriaux C; Gaudy C; Gérard E; Giacchero D; Granel-Brocard F; Grange F; Jouary T; Kramkimel N; Lebbé C; Le Corre Y; Legoupil D; Lesage C; Lesimple T; Lorphelin JM; Mansard S; Martin L; Mary-Prey S; Maubec E; Meyer N; Mignard C; Montaudie H; Mortier L; Nardin C; Neidhardt Berard EM; Pagès Laurent C; Peuvrel L; Quereux G; Robert C; Saiag P; Saint-Jean M; Samimi M; Sassolas B; Scalbert C; Skowron F; Steff M; Stoebner PE; Trablesi S; Visseaux L; Zehou O; Boespflug A;
Ann Dermatol Venereol; 2024 Mar; 151(1):103243. PubMed ID: 38325268
[No Abstract] [Full Text] [Related]
17. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
18. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
19. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
[TBL] [Abstract][Full Text] [Related]
20. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
